Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Beximco Pharmaceuticals Limited (BXP.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
102.000.00 (0.00%)
At close: 11:16AM GMT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close102.00
Open100.10
Bid95.00 x 0
Ask107.00 x 0
Day's Range100.10 - 100.10
52 Week Range65.00 - 112.00
Volume149
Avg. Volume34,061
Market Cap867.978M
Beta (5Y Monthly)0.77
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.01 (1.35%)
Ex-Dividend DateNov 23, 2020
1y Target Est84.00
  • Reuters

    UPDATE 2-Bangladesh's Beximco to sell first generic version of Merck COVID-19 pill

    A Bangladeshi drugmaker will soon begin selling the world's first generic version of Merck's COVID-19 pill, molnupiravir, which has been touted as a potential game-changer in the fight against the pandemic. Beximco Pharmaceuticals will first sell generic molnupiravir in Bangladesh before considering exports based on global regulatory approvals, it said on Tuesday. The generic version has received emergency use authorisation from Bangladesh's drug regulators.

  • Reuters

    Bangladesh's Beximco to sell first generic version of Merck COVID-19 pill

    (Reuters) -A Bangladeshi drugmaker will soon begin selling the world's first generic version of Merck's COVID-19 pill, molnupiravir, which has been touted as a potential game-changer in the fight against the pandemic. Beximco Pharmaceuticals will first sell generic molnupiravir in Bangladesh before considering exports based on global regulatory approvals, it said on Tuesday. The generic version has received emergency use authorisation from Bangladesh's drug regulators.

  • Reuters

    Serum Institute of India delays vaccines for private sale in Bangladesh; focus on state campaigns

    Beximco is Bangladesh's exclusive distributor of the Oxford University-AstraZeneca shot that SII, the world's biggest vaccine manufacturer, is producing in bulk for low- and medium-income countries. The Bangladeshi company last week received 5 million of the 30 million doses it had ordered from SII for Bangladesh's immunisation programme that begins next week. Beximco had separately ordered 1 million doses for sale on the private market, with the hope to start marketing it this month.

Advertisement
Advertisement